» Articles » PMID: 11161851

Occult Lymph Node Metastases Detected by Cytokeratin Immunohistochemistry Predict Recurrence in Node-negative Endometrial Cancer

Overview
Journal Gynecol Oncol
Date 2001 Feb 13
PMID 11161851
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Even after curative resection of early endometrial cancer, some patients die as a result of recurrence. We believe that these patients likely had occult lymph node metastases at the time of diagnosis. In an attempt to identify the responsible occult metastases, the clinicopathological significance of cytokeratin expression in lymph nodes with unconfirmed metastasis was evaluated retrospectively in patients with endometrial carcinoma.

Methods: We examined 304 pelvic lymph nodes and 46 primary tumors excised from 46 patients with endometrial cancer, including 36 with Stage I disease and 10 with Stage IIIc disease. Formalin-fixed paraffin-embedded tissue sections were stained immunohistochemically using antibodies against cytokeratin, CA125, and macrophage-related antigen. Sections were also stained with hematoxylin and eosin.

Results: In 10 patients with Stage IIIc disease, cytokeratin expression was detected in cells other than the tumor cells in all 13 lymph nodes with metastasis and also in 20 (30.3%) of 66 lymph nodes without metastasis. Cytokeratin expression was observed in 37 (16.4%) of 225 lymph nodes with unconfirmed metastasis, which were obtained from 14 of 36 patients with Stage I disease. Five of fourteen patients with lymph nodes expressing cytokeratin had recurrent disease in the pelvic cavity, while all 22 patients with unconfirmed cytokeratin expression in their lymph nodes showed no recurrence. Cytokeratin and CA125 were detected simultaneously on macrophages in lymph nodes. Cytokeratin expression in lymph nodes was closely related to lymph-vascular space involvement of the primary tumor, but was not related to either histological grade or depth of myometrial invasion. Multivariate analysis identified cytokeratin expression as an independent risk factor for recurrence in Stage I endometrial cancer.

Conclusions: The immunohistochemical expression of cytokeratin in lymph nodes with undetected metastases predicts occult metastasis to these nodes and is a risk factor for recurrence in early-stage endometrial cancer.

Citing Articles

Low-Volume Metastases in Apparent Early-Stage Endometrial Cancer: Prevalence, Clinical Significance, and Future Perspectives.

Fumagalli D, De Vitis L, Caruso G, Occhiali T, Palmieri E, Guillot B Cancers (Basel). 2024; 16(7).

PMID: 38611016 PMC: 11011093. DOI: 10.3390/cancers16071338.


The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis.

Ronsini C, Napolitano S, Iavarone I, Fumiento P, Vastarella M, Reino A J Clin Med. 2024; 13(5).

PMID: 38592342 PMC: 10932314. DOI: 10.3390/jcm13051496.


The impact of lymphadenectomy on ovarian clear cell carcinoma: a systematic review and meta-analysis.

Liu Y, Geng F, Zhang H, Xue J, Chu R World J Surg Oncol. 2024; 22(1):37.

PMID: 38287354 PMC: 10823682. DOI: 10.1186/s12957-024-03324-6.


Predictors for the Recurrence of Clinically Uterine-Confined Endometrial Cancer and the Role of Cytokeratin Immunohistochemistry Stain in the Era of Sentinel Lymph Node Mapping.

Ting W, Hsieh S, Chen H, Wei M, Lin H, Hsiao S Cancers (Basel). 2022; 14(8).

PMID: 35454878 PMC: 9031387. DOI: 10.3390/cancers14081973.


Cytokeratin Expression Pattern in Human Endometrial Carcinomas and Lymph Nodes Micrometastasis: a Mini-review.

Vasilevska D, Rudaitis V, Adamiak-Godlewska A, Semczuk-Sikora A, Lewkowicz D, Vasilevska D J Cancer. 2022; 13(6):1713-1724.

PMID: 35399711 PMC: 8990429. DOI: 10.7150/jca.70550.